Fintel reports that on April 10, 2025, Scotiabank downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) from ...

Fintel reports that on April 10, 2025, HC Wainwright & Co. downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) ...

HC Wainwright reaffirmed their neutral rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a report published on Thursday morning, Marketbeat reports. They currently have a $ ...

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular ...

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer ...

Tempest Therapeutics (TPST) announced that the company plans to explore a full range of strategic alternatives to advance its clinical stage programs. Strategic alternatives under consideration ...

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

BRISBANE, Calif. - Tempest Therapeutics, Inc. (NASDAQ:TPST), a biotech firm specializing in cancer therapeutics, is exploring strategic alternatives to enhance stockholder value, including ...

Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets'.

Tempest Therapeutics is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements. Shares rose 9.2% to $7.81 in post ...